Latest news with #Omada
Yahoo
a day ago
- Business
- Yahoo
Wall Street analysts start bullish on Omada Health on chronic care market growth
-- Barclays, Goldman Sachs, JP Morgan and Morgan Stanley issued bullish rating on Omada Health stock saying the virtual‑care provider could capture more of the large market for diabetes, hypertension and weight‑management services. Barclays began at 'overweight' with a $21 price target, arguing Omada's new GLP‑1 weight‑loss programme should speed adoption of its digital coaching platform. Goldman Sachs started at 'buy' and set the Street‑high target of $29, saying a focus on measured clinical outcomes can help the company outgrow peers. JP Morgan initiated at 'overweight' with a $19 target and projected roughly 24% compound annual revenue growth through 2027 as Omada expands its corporate client base. Morgan Stanley also rated the stock 'overweight' and set a $25 target, citing scope for margin gains as artificial‑intelligence tools automate parts of the service. The brokerages see Omada tapping a U.S. population in which more than 150 million people live with at least one chronic condition. Several analysts said last year's introduction of an integrated care track for users of GLP‑1 weight‑loss drugs, and recent partnerships with pharmacy‑benefit giants CVS Caremark and Express Scripts, should widen the company's reach. San Francisco‑based Omada raised $158 million in its Nasdaq debut on June 6, pricing shares at $19. The stock has since traded below that level but is up roughly 20% from its low. Analysts said Omada's move toward break‑even, targeted for the second half of 2026 or 2027 depending on the forecast, gives management flexibility to invest in new products while trimming debt. The company was valued at about $1.4 billion, or just under three times projected 2026 revenue, a discount to digital‑health peers, the broker notes said. Related articles Wall Street analysts start bullish on Omada Health on chronic care market growth UBS hires Morgan Stanley's Taylor Henricks to head M&A in Americas INmune slides again as Scotiabank, RJ cut ratings after Alzheimer's drug miss
CNBC
a day ago
- Business
- CNBC
Goldman says this newly public obesity play can surge nearly 60%
Newly public virtual care company Omada Health is a strong pick for investors seeking long-term growth, according to Goldman Sachs. Analyst David Roman initiated coverage of Omada Health with a buy rating and 12-month price target of $29. That suggests roughly 58.5% potential upside ahead for the stock, which made its public debut on the Nasdaq on June 6. "At current levels — considering the growth trajectory of the business, near-term path to profitability, and below peer valuation — we see OMDA offering compelling risk/reward," Roman wrote in a Monday note to clients. Roman is particularly bullish on Omada's clinical value proposition and growth trajectory driven by its programs. Omada employs what it describes as a "between-visit care model" to virtually support patients with chronic conditions tied to obesity— such as prediabetes, diabetes and hypertension — between their regular doctor's appointments. According to Roman, the Omada program has seen strong results from clinical and economic studies, adding to its growth trajectory and value proposition for stakeholders. The company's approach has "resulted in an engaging patient experience, robust clinical evidence which we believe will be increasingly important to employer-customer decision markers, and a strong ROI proposition that should resonate with payors," he said. Separately, Roman believes that Omada has significant room to grow given that roughly 156 million patients in the U.S. have 1 or more chronic conditions, and because the cost burden of chronic conditions in the U.S. sits at over $1 trillion annually. "The company sits within a large are growing market opportunity where there are significant unmet needs and secular drivers of growth," he said. The San Francisco-based company has seen skyrocketing growth , boasting a 57% increase in first-quarter revenue to $55 million from $35.1 million during the same period last year. Omada generated $169.8 million in revenue in 2024, up 38% from $122.8 million the previous year. Looking ahead, Roman is optimistic that Omada's partnerships with weight management program EncircleRx and CVS, along with its GLP-1 program, could drive higher revenue growth. Omada went public in early June, pricing its IPO at $19 per share. Since then, however, shares are down slightly.
Yahoo
18-06-2025
- Business
- Yahoo
Omada Health releases new data on its GLP-1 companion program
Omada Health (OMDA) released new data demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss. Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings. Omada analyzed 1,124 members without diabetes who self-reported GLP-1 use to assess the impact of its Enhanced GLP-1 Care Track on medication persistence through 24 weeks. Self-reported medication initiation and persistence were confirmed using objective pharmacy claims data. Previous real-world studies have demonstrated a wide range in medication persistence rates at 12 weeks, 42% to 80%, and 24 weeks, 33% to 74%, after starting GLP-1s. In contrast, members included in this analysis of Omada's Enhanced GLP-1 Care Track demonstrated higher persistence rates-94% through 12 weeks and 84% through 24 weeks Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on OMDA: Disclaimer & DisclosureReport an Issue Omada Health Completes Successful Initial Public Offering
Yahoo
17-06-2025
- Health
- Yahoo
Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada's companion program can help sustain GLP-1 use, delivering on clinical trials' promises SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in the first month, and less than half stayed on for more than 12 weeks.4 These data suggest that in the real world, factors like non-persistent medication use mean that many who use GLP-1s for weight management may not see the results reflected in clinical trials. 'While published literature illustrates the incredible potential of GLP-1s, these outcomes are generally limited to those who consistently use their medication long enough to see benefit. In the real world many patients do not receive the necessary support for this to be a reality,' said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. 'Omada's GLP-1 companion program helps individuals maintain their medication regimen and, in this analysis, helped members achieve clinical trial-level outcomes in real-world settings, which sets the stage for cardiometabolic disease reduction.' Omada analyzed 1,124 members without diabetes who self-reported GLP-1 use to assess the impact of its Enhanced GLP-1 Care Track on medication persistence through 24 weeks. Self-reported medication initiation and persistence were confirmed using objective pharmacy claims data. Previous real-world studies have demonstrated a wide range in medication persistence rates at 12 weeks (42%4 to 80%5) and 24 weeks (33%6 to 74%5) after starting GLP-1s. In contrast, members included in this analysis of Omada's Enhanced GLP-1 Care Track demonstrated higher persistence rates—94% through 12 weeks and 84% through 24 weeks.1 This analysis also found the average weight loss for Omada members that persisted on their medication through 24 weeks was closely aligned with 24-week outcomes from a recent head-to-head clinical trial7 comparing tirzepatide and semaglutide in a similar population. Whereas Omada members who stopped taking their GLP-1 medication any time before 24 weeks lost an average of 7.4% of their body weight, those who remained on their medication through 24 weeks lost an average of 12.1%—a 64% relative increase.1 Providing the right kind of support to enable members to persist with their GLP-1 medication long enough to see benefits can help them achieve clinical trial-level weight loss outcomes, setting the stage for cardiometabolic disease risk reduction. Omada's Enhanced GLP-1 Care Track provides targeted resources for members as they move through their GLP-1 use journey. Members in this companion program receive high-touch care team support to help overcome common barriers to persistence – from education around dose titration, common side effects, and mitigation strategies to nutrition guidance and support from Exercise Specialists to combat muscle loss. Members who plan to stop their medication due to access concerns may receive resources that help them understand their options and navigate the larger healthcare ecosystem. 'We are in the fortunate position that more patients are getting access to these transformative medications,' said Wei-Li Shao, President, Omada Health. 'However, with increased access comes the responsibility to ensure GLP-1 use remains cost-effective by supporting sustainable long-term health benefits. We believe these findings highlight the potential of Omada's program to enhance clinical outcomes with improved medication persistence and a focus on engagement in healthy lifestyle behavior changes." This analysis was conducted through Omada's Insights Lab as part of the ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) initiative, and builds on more than a decade of insights and 29 peer-reviewed publications assessing the efficacy of behavior change programs to improve chronic disease management. Omada HealthOmada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 29 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada's scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s. The foundation of Omada's success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement's Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently. ContactsRose Ramsethpress@ 1Chang, H., Devaraj, S. M., Naqvi, J. B., & Linke, S. (2025). GLP-1 Medication Persistence, a Key Component of Weight Loss. Omada Health. GLP-1 Medication Persistence, a Key Component of Weight Loss. Omada Health. H., Butsch, W. S., Schulte, R., Casacchia, N. J., Le, P., Boyer, C. B., Griebeler, M. L., Burguera, B., & Rothberg, M. B. (2025). Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity, 2025, 1-11. Y., Choi, T., & Al-Aly, Z. (2025). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature, 31, 951–962. Health Intelligence®. (2024, May). Real‑world trends in GLP‑1 treatment persistence and prescribing for weight management [PDF]. Blue Cross Blue Shield Association. Retrieved June 16, 2025, from 5Hankosky, E. R., Karishma, D., Chinthammit, C., Grabner, M., Stockbower, G., He, X., Mojdami, D., Wenziger, C., & Gibble, T. H. (2025). Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes & Metabolism, 51 (3), 101636. P. P., Urick, B. Y.,Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024). Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy, 30 (8), 860-867. 7Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Valderas, E. G., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, NEJM, 2025. in to access your portfolio
Forbes
11-06-2025
- Health
- Forbes
InnovationRx: RFK Jr. Purges The Vaccine Advisory Committee
In this week's edition of InnovationRx, we look at RFK Jr.'s vaccine advisory committee purge, a tech billionaire's funding of research on AI and healthcare, Omada's IPO and more. To get it in your inbox, subscribe here. On Monday, Health and Human Services Secretary Robert F. Kennedy Jr. purged the group that advises the CDC on vaccines in order to replace its members with those of his own choosing. The group, known as the Advisory Committee on Immunization Practices, or ACIP, is composed of 17 vaccination experts and is generally not political. In a Wall Street Journal editorial, Kennedy claimed that 'a clean sweep is needed to re-establish public confidence in vaccine science.' The move by RFK Jr., who has long expressed antipathy toward vaccinations and promoted conspiracy theories, was roundly condemned by public health experts. It typically takes a year to vet individual members of the panel, but the new members appear to be scheduled to meet at the next scheduled ACIP meeting in Atlanta later this month. The American Medical Association criticized the ousters in a statement, saying that it 'undermines trust and upends a transparent process that has saved countless lives.' The association noted that it would 'fuel the spread of vaccine-preventable illnesses' at a time when the measles outbreak was ongoing and routine child vaccination rates have been declining. Even before the purge, Kennedy had been chipping away at vaccines. Late last month, he eliminated recommendations for pregnant women and healthy children to receive COVID-19 vaccinations, a move that caused the American Pharmacists' Association to withhold endorsement of the CDC's current COVID vaccination schedule this week. Trump's first Surgeon General, Dr. Jerome Adams, wrote in Time on Tuesday that the changes 'not only jeopardize public health but also threaten to erode trust in our health institutions at a critical time.' Dr. Paul Offit, an infectious disease expert and member of the FDA's independent panel of vaccine advisors, told ABC News that RFK's latest move was extremely dangerous. '[Kennedy] doesn't have a single example to show where a vote by one of these committees has hurt children,' he said. 'In fact, the opposite is true–the votes by this committee over the last 25 years have caused children to suffer less and die less. ACIP should be given awards, not fired.' Samsara cofounder and CEO Sanjit Biswas Samsara Samsara cofounder and CEO Sanjit Biswas built his business by applying AI to an area where that was unusual for its time: industrial and physical operations. Now Biswas, who is worth $4.8 billion by Forbes estimates, wants to apply similar technology to healthcare with his philanthropy. After taking $25 billion (market cap) Samsara public in December 2021, Biswas and his wife Hope Biswas, who has a Ph.D. in epidemiology, established the Biswas Family Foundation with $100 million in funding. The group began making grants in 2023, and has been giving away funds in batches of $15 million a year since. The grants are typically $3 million to $4 million each. 'I have always thought about technology as a way to have a tremendous amount of impact on the world,' Biswas tells Forbes. With the foundation, he hopes to find the sweet spot between startups, which already have access to VC funding, and pure scientific research that's years or even decades away from commercialization—work that, as Biswas puts it, has 'translational impact.' One area that Biswas has funded: using AI to find new uses for existing drugs. One effort he's funded, led by Marinka Zitnik, a biomedical informatics researcher at Harvard Medical School, is building a comprehensive benchmark for computational drug repurposing. While physicians have long prescribed drugs off-label, 'it's not done in a systematic way,' Biswas says. With this project, he hopes researchers will be able to find new uses for existing drugs at scale, including for rare diseases, with the help of tools like deidentified medical records.. Another Biswas-funded project, led by Stanford University's Anshul Kundaje, aims to develop an AI chatbot with access to genomic knowledge to improve diagnosis of cardiovascular disease. And a third effort, led by Katherine Pollard, director of data science and biotechnology at the Gladstone Institutes, is developing personalized diagnosis and treatment for colorectal and skin cancers using machine learning models, which can fit the right treatment to the specific genetic mutation of a patient's tumor. In addition to longstanding researchers like these, Biswas's foundation last December began funding a group of MIT post-doctoral researchers in areas that include AI and health and low-cost diagnostics. These early-career scientists are more likely to stay in the field if they can get funding at that stage, Biswas says—something that's especially critical right now given the drastic cutbacks to NIH and NSF funding under Trump. The Administration's cutbacks have been so large that private efforts—even enormous ones like Bill Gates' recently announced plans to wind down his foundation and give away $200 billion in 20 years—can't possibly fill the gap. While acknowledging the scale of that hole, Biswas (who says that 'in another life I would go do a doctoral dissertation in this area for sure') notes that he plans to increase his philanthropic commitment over time to fund research at the intersection of AI and medicine to better diagnose and treat disease. 'We are leaning in more heavily,' he says. 'The number will go up over time.' On Monday, the FDA approved a new monoclonal antibody from Merck to protect against RSV. The new drug, clesrovimab, will be sold under the brand name Enflonsia. The drug protects infants from RSV shortly before their first season of the disease, which is typically in the fall or winter. In clinical trials, the drug reduced RSV-related hospitalizations by 84%. Sanofi and AstraZeneca already market a similar drug, called Beyfortus, but Enflonsia is simpler because all babies get the same dose in an injection, while the proper dose for Beyfortus depends on the weight of the baby. 'It doesn't matter if the baby's small or if the baby's large–a single shot is sufficient,' Merck's chief medical officer Eliav Barr told Forbes. The next step for Enflonsia is to be evaluated by ACIP later this month, assuming the advisory group still meets as scheduled after its shakeup. Barr said that Merck plans to be ready to bring the drug to market in time for RSV season. Virtual care company Omada Health went public on Friday, following digital health company Hinge Health by a few weeks. The company raised some $150 million from the IPO. That new capital will help Omada (which now has a market cap of $1 billion) expand its business, CEO Sean Duffy said. It currently has more than 700,000 people under active care management for chronic diseases such as diabetes, 31% of whom actually use the company's platform to care for multiple chronic conditions. Omada's shares shot up Friday, closing at $23, a 21% gain over the initial price of $19. But by Tuesday, investors had pushed the stock back down, to $18. The American Academy of Medical Colleges detailed the impact of the Trump Administration's proposed budget cuts on hospital systems in a report released Wednesday. Changes to student loan programs will likely reduce the number of medical students, which will exacerbate the existing doctor shortage at hospitals, according to the report. Proposed changes to how outpatient care is reimbursed could cost hospitals $167 billion over the next 10 years, while proposed cuts to Medicare reimbursement rates will strain already fragile hospital finances. And, of course, NIH budget cuts will eliminate needed research and cancel clinical trials for new medicines. 'Proposed federal actions on multiple fronts not only jeopardize scientific discovery and individual Medicaid patients who might lose health insurance,' the report said. 'They jeopardize the entire academic medicine ecosystem.' Federal lawmakers grilled 23andMe's leaders on the protection of customers' genetic information during the company's bankruptcy sale. Senators from both parties pushed back against the Trump Administration's proposed $18 billion cut to the NIH. 'For God's sake, we lead the world in medical research. Why would we give up on it?' Senator Dick Durbin, Dem.-Ill., said after noting that Northwestern University had not received any NIH funding for 11 weeks. China has adopted a number of policies to incentivize scientists to do their research there. Hundreds of NIH staff signed a letter criticizing proposed cuts to the agency, writing that '[w]e are compelled to speak up when our leadership prioritizes political momentum over human safety and faithful stewardship of public resources.' AI biotech company Recursion laid off 20% of its staff following its pipeline cutback. The company said in an SEC filing that the staff cuts would cost around $11 million in severance and related expenses.
